A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Trial Profile

A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Tabelecleucel (Primary)
  • Indications Lymphoproliferative disorders; Non-Hodgkin's lymphoma; Post-transplant lymphoproliferative disorder
  • Focus Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 17 Jun 2018 Long-term survival results from protocols 11-130 and 95-024 presented at the 23rd Congress of the European Haematology Association
    • 15 Jun 2018 Results presented in the Atara Biotherapeutics media release.
    • 15 Jun 2018 According to an Atara Biotherapeutics media release, data from this trial was presented at the 23rd Congress of the European Hematology Association (EHA) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top